EQS-News

DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE

EQS-News: Defence Therapeutics Inc. / Key word(s): Product Launch DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE 26.03.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement.

_________________________________________________________________

CSE: DTC  FSE: DTC  OTCQB: DTCFF       PRESS RELEASE

 

DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX ANTI-CANCER ARM^TM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002^TM VACCINE

 

Vancouver, BC, Canada, March 26th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biotechnology company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful testing of a second-generation anti-cancer vaccine, called ARM-002TM, using its lead anti-cancer molecule AccuTOX. When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.

 

Compared to current anti-cancer strategies, vaccination can stimulate specific immune responses capable of potentially curing established tumors. In addition, developed immune cells can lead to a long-lasting memory response capable of further protecting the patient from subsequent cancer relapses. Using mesenchymal stromal cells (MSCs) as a vaccination platform; Defence has previously shown that it is possible to pharmacologically reprogram these immune-suppressive cells into potent antigen presenting cells using its Accum derivative called A1 (ARM^TM vaccine). Although the ARM^TM vaccine can effectively present antigens to responding T cells, the large amount of antigen preparation required to generate the cellular vaccine might represent challenges in the clinic. Defence elected to test its lead AccuTOX molecule to engineer a second-generation anti-cancer vaccine as the latter was shown to directly enhance antigen presentation in cancer cells if delivered intratumorally at lower doses.